Jun-Jun Yeh

Prof. Dr. Jun-Jun Yeh

Chia-Yi Christian Hospital, Chiayi City, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
WCW-S. Chung
W-S. Chung
CLC-L. Lin
C-L. Lin
CHC-T. Hung
C-T. Hung
YCY-H. Chu
Y-H. Chu
FSF-C. Sung
F-C. Sung
Jun-Jun YehJun-Jun Yeh
Jun-Jun Yeh
To evaluate the effects of pulmonary tuberculosis (PTB) on the risk of subsequent acute coronary syndrome (ACS) development. The incidence and risk factors of ACS were investigated in 10 168 newly diagnosed tuberculosis (TB) patients from Taiwan's National Health Insurance Research Database between 1997 and 2010, and 40 672 controls without TB from the general population. The follow-up period ran from the diagnosis of new TB to the date of the ACS event, censoring or 31 December 2010. During the follow-up period, the overall incidence of ACS was higher in TB patients than in non-TB patients (2.10 vs. 1.51 per 1000 person-years). The incidence of ACS increased by 40% in TB patients after adjusting for age, sex and co-morbidities. Male sex, age, hypertension and diabetes were independent factors for the risk of ACS development. The probability of ACS increased in the years following the TB diagnosis. This nationwide population-based cohort study provides compelling evidence that TB patients are at higher risk of developing ACS, and that the risk increases with age. Clinicians should be aware of this and strive to reduce ACS risk factors in TB patients.

29 August 2013 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
WCWei-Sheng Chung
Wei-Sheng Chung
CLCheng-Li Lin
Cheng-Li Lin
FHFeng-Ming Ho
Feng-Ming Ho
RLRuei-Yuan Li
Ruei-Yuan Li
FSFung-Chang Sung
Fung-Chang Sung
Jun-Jun YehJun-Jun Yeh
Jun-Jun Yeh
Studies on the association between asthma and pulmonary thromboembolism are considerably limited. We investigated whether pulmonary embolism is associated with asthma using a nationwide cohort study.We identified 31 356 patients with newly diagnosed asthma in 2002–2008 and 125 157 individuals without asthma randomly selected from the general population, frequency matched by age, sex and index year using the National Health Insurance Research Database. Both cohorts were followed-up until the end of 2010 to measure the incidence of pulmonary embolism. Cox proportional hazards regression analysis was used to measure the hazard ratio of pulmonary embolism for the asthmatic cohort, compared with the nonasthmatic cohort.We followed 186 182 person-years for asthmatic patients and 743 374 person-years for nonasthmatic subjects. The hazard ratio of pulmonary embolism was 3.24 for the asthmatic cohort, compared with the nonasthmatic cohort after adjusting for sex, age, comorbidities and oestrogen supplementation. The risk of developing pulmonary embolism significantly increased with the increased frequency of asthma exacerbation and hospitalisation.This nationwide cohort study suggests that the risk of developing pulmonary embolism is significantly increased in asthmatic patients compared to the general population. Frequent asthma exacerbation and hospitalisation are significantly associated with pulmonary embolism risk.

22 April 2011 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
JLJ.-A. Liang
J.-A. Liang
LSLi-Min Sun
Li-Min Sun
Jun-Jun YehJun-Jun Yeh
Jun-Jun Yeh
FSFung-Chang Sung
Fung-Chang Sung
SCShih-Ni Chang
Shih-Ni Chang
CKChia-Hung Kao
Chia-Hung Kao
Patients with end-stage renal disease are suggestive to have a higher risk for the development of some kinds of cancer. The aim of this study is to evaluate the possible association between malignancy and end-stage renal disease in Taiwan. We used the data of the National Health Insurance system of Taiwan to assess this issue. The end-stage renal disease cohort contained 21 817 patients, and each patient was randomly frequency-matched with two people from the general population without end-stage renal disease based on their age and sex. The Cox proportional hazard regression analysis was conducted to estimate the effects of end-stage renal disease on the cancer risk. In patients with end-stage renal disease, the risk of developing overall cancer was significantly higher than the normal healthy subjects (adjusted hazard ratio = 1.64, 95% confidence interval = 1.54–1.74). This was also true when we analyzed males and females separately. For individual cancer, the risks for developing urinary tract cancers, liver cancer and breast cancer among patients with end-stage renal disease were significantly higher. On the contrary, lung, prostate and esophageal cancer risks were significantly lower when compared with the normal healthy subjects. Our study found Taiwanese patients with end-stage renal disease to have a higher risk to develop urinary tract, liver and breast cancer. We unexpectedly discovered these patients to have a lower risk to get lung, prostate and esophageal cancer.

1 March 2012 in Academic Radiology
Verified
Journal Article
Closed access
MCMing-Che Chang
Ming-Che Chang
JCJin-Hua Chen
Jin-Hua Chen
JLJi-An Liang
Ji-An Liang
CLCheng-Chieh Lin
Cheng-Chieh Lin
KYKuang-Tao Yang
Kuang-Tao Yang
CKChia-Hung Kao
Chia-Hung Kao

1 February 2003 in Respiration
Verified
Journal Article
Closed access
Jun-Jun YehJun-Jun Yeh
Jun-Jun Yeh
WHW.H. Hsu
W.H. Hsu
JWJ.J. Wang
J.J. Wang
SHS.T. Ho
S.T. Ho
AKA. Kao
A. Kao
Background: It was reported that multidrug resistance gene 1 (MDR1) encoding human P-glycoprotein (Pgp) may play an important role in multidrug resistance of lung cancer. Therefore, before initiating chemotherapy, it is important to accurately determine the presence of Pgp in lung cancer, to achieve a satisfactory chemotherapy response. Objectives: The aim of this study was to compare immunohistochemical analyses of Pgp expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 50 patients with stage IIIb or IV NSCLC were enrolled in this study. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the 3rd month after completion of treatment by clinical and radiological methods. Results: All of the 28 (100%) cases with good response had negative Pgp expression and 15 of the 22 (68%) cases with poor response had positive Pgp expression (p < 0.05). No significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between good response and poor response groups. Conclusions: Although Pgp expression in NSCLC does not fully predict chemotherapy response to paclitaxel-based therapy, detection of Pgp expression will aid in planning paclitaxel-based therapy for patients with advanced NSCLC. Further studies with a larger number of patients and a longer time of follow-up are necessary to confirm our findings.

23 October 2013 in Lung
Verified
Journal Article
Closed access
PDF file
TLTe-Yu Lin
Te-Yu Lin
WHWen-Yen Huang
Wen-Yen Huang
JLJung-Chung Lin
Jung-Chung Lin
CLCheng-Li Lin
Cheng-Li Lin
FSFung-Chang Sung
Fung-Chang Sung
Jun-Jun YehJun-Jun Yeh
Jun-Jun Yeh